Search results for Alzheimer's Drug

Breakthrough Alzheimer’s Drug Rewires the Brain Instead of Just Clearing Plaques

An experimental drug is showing promise by targeting Alzheimer’s disease at the level of gene regulation. Researchers at the University of Barcelona have developed an experimental...

Parkinson’s Drug Restores Memories in Alzheimer’s

Severe dopamine dysfunction in the entorhinal cortex is a primary, hidden mechanism behind Alzheimer's-related memory impairment. Researchers found that dopamine levels in this vit...

New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes

THURSDAY, April 16, 2026 — New anti-amyloid drugs approved to treat Alzheimer’s disease have no clinically meaningful positive effects for patients, a major evidence review has co...

Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axso...

Experimental Alzheimer’s drug could reduce alcohol withdrawal damage, researchers say

Researchers say an experimental Alzheimer's drug may calm brain inflammation linked to alcohol withdrawal, potentially reducing relapse and neural damage.

'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again

The anti-amyloid drug class has yielded some FDA approvals and plenty of failed candidates. Now, researchers are looking at the overall track record of the group and painting an un...

Alzheimer’s Drugs Have No ‘Meaningful Effect’ on Cognitive Decline: Review

By Zachary Stieber A class of Alzheimer’s drugs that have only been available for several years did not appear to have any “clinically meaningful effects,” according to a new revie...

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2...

‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s

This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.

<![CDATA[FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers]]>

Current Clinical Trials of Alzheimer’s Drugs

This month, a group of researchers published an annual report on the clinical trials that are testing drugs for Alzheimer’s disease. Overall, they reported an increase in the numbe...

New Math Method Inflates Alzheimer’s Drug Success by 29x

A critical research lette exposes severe flaws in "quantile aggregation", a statistical technique recently used by pharmaceutical researchers to evaluate the drug donanemab.

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint.

A protective gene sent to the liver cleared amyloid from mouse brains, sparking hope for an Alzheimer’s gene therapy

The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle to penetrate the barrier protecting the mind from outsid...

Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks

Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explai...

Alzheimer’s drugs may not work and could raise brain risks

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major...

The Brain Is Braking Too Hard. A New Drug Target Could Release the Handbrake on Memory

Deep in the hippocampus, a molecular miscommunication is strangling memory. Long before a person with Alzheimer’s disease forgets a name or loses track of a familiar face, their ne...

Some Alzheimer's drugs make 'no meaningful difference'

Drugs that are said to slow the progression of Alzheimer's disease "make no meaningful difference to patients" while increasing the risk of swelling and bleeding in the brain, acco...

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently...

Transforming neurodegenerative disease treatment

Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.

These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit the market in the last few years — really help slow...

USC scientists discover a hidden Alzheimer’s trigger and a possible way to shut it down

USC researchers have identified potential new drug compounds that may reduce the brain inflammation linked to Alzheimer’s disease, especially in people with the high-risk APOE4 gen...

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.